Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cassava sciences - SAVA

SAVA

Close Chg Chg %
26.05 6.13 23.53%

Closed Market

32.18

+6.13 (23.53%)

Volume: 4.65M

Last Updated:

Nov 21, 2024, 4:00 PM EDT

Trade Now

Company Overview: cassava sciences - SAVA

SAVA Key Data

Open

$26.13

 Day Range

26.03 - 33.98

52 Week Range

8.79 - 42.20

 Market Cap

$1.25B

Shares Outstanding

48.11M

 Public Float

41.77M

Beta

-0.58

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.36

Yield

0.00%

 Dividend

$0.75

EX-DIVIDEND DATE

Dec 13, 2012

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.55M

  

SAVA Performance

1 Week
 
 19.58%
 
1 Month
 
 21.21%
 
3 Months
 
 3.97%
 
1 Year
 
 50.73%
 
5 Years
 
 2,337.88%
 

SAVA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About cassava sciences - SAVA

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

SAVA At a Glance

Cassava Sciences, Inc.
6801 North Capital of Texas Highway
Austin, Texas 78731
Phone 1-512-501-2444 Revenue 0.00
Industry Biotechnology Net Income -97,217,000.00
Sector Health Technology Employees 29
Fiscal Year-end 12 / 2024
View SEC Filings

SAVA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 6.916
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -7.879
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

SAVA Efficiency

Revenue/Employee N/A
Income Per Employee -3,352,310.345
Receivables Turnover N/A
Total Asset Turnover N/A

SAVA Liquidity

Current Ratio 9.132
Quick Ratio 9.132
Cash Ratio 8.534

SAVA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -50.307
Return on Equity -53.269
Return on Total Capital -70.72
Return on Invested Capital -53.263

SAVA Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cassava Sciences - SAVA

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
22.00K 534.00K 1.30M 1.53M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
22.00K 534.00K 1.30M 1.53M
Depreciation
22.00K 310.00K 804.00K 1.08M
Amortization of Intangibles
- 224.00K 497.00K 446.00K
COGS Growth
-62.07% +2,327.27% +143.63% +17.60%
Gross Income
(22.00K) (534.00K) (1.30M) (1.53M)
Gross Income Growth
+62.07% -2,327.27% -143.63% -17.60%
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
11.01M 36.23M 79.62M 104.43M
Research & Development
7.29M 28.71M 68.93M 89.42M
Other SG&A
3.72M 7.52M 10.69M 15.00M
SGA Growth
+14.32% +229.13% +119.74% +31.16%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(11.03M) (36.77M) (80.92M) (105.96M)
Non Operating Income/Expense
4.70M 4.38M 4.67M 8.74M
Non-Operating Interest Income
112.00K 49.00K 2.78M 7.83M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(6.33M) (32.38M) (76.25M) (97.22M)
Pretax Income Growth
-36.77% -411.29% -135.44% -27.50%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(6.33M) (32.38M) (76.25M) (97.22M)
Minority Interest Expense
- - - -
-
Net Income
(6.33M) (32.38M) (76.25M) (97.22M)
Net Income Growth
-36.77% -411.29% -135.44% -27.50%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(6.33M) (32.38M) (76.25M) (97.22M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(6.33M) (32.38M) (76.25M) (97.22M)
EPS (Basic)
-0.2426 -0.8218 -1.8966 -2.3184
EPS (Basic) Growth
+8.80% -238.75% -130.79% -22.24%
Basic Shares Outstanding
26.11M 39.41M 40.20M 41.93M
EPS (Diluted)
-0.2426 -0.8218 -1.8966 -2.3184
EPS (Diluted) Growth
+8.80% -238.75% -130.79% -22.24%
Diluted Shares Outstanding
26.11M 39.41M 40.20M 41.93M
EBITDA
(11.01M) (36.23M) (79.62M) (104.43M)
EBITDA Growth
-14.32% -229.13% -119.74% -31.16%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 107.00
Number of Ratings 2 Current Quarters Estimate -0.40
FY Report Date 12 / 2024 Current Year's Estimate -0.83
Last Quarter’s Earnings -0.58 Median PE on CY Estimate N/A
Year Ago Earnings -2.32 Next Fiscal Year Estimate 0.50
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 N/A 2 1
Mean Estimate -0.40 N/A -0.83 0.50
High Estimates -0.36 N/A -0.42 0.50
Low Estimate -0.44 N/A -1.24 0.50
Coefficient of Variance -14.14 N/A -69.86 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 1
OVERWEIGHT 0 0 0
HOLD 0 1 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Overweight Overweight

Insider Actions for Cassava Sciences - SAVA

Date Name Shares Transaction Value
May 23, 2024 Remi Barbier President & CEO; Director 50,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Eric J. Schoen Chief Financial Officer 25,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Robert Christopher Cook SVP & General Counsel 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 James W. Kupiec Chief Medical Officer 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 Sanford R. Robertson Director 950,851 Bona fide gift 0.00
May 17, 2024 Sanford R. Robertson Director 5,000 Bona fide gift 0.00
May 14, 2024 Robert Z. Gussin Director 15,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Pierre Gravier Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Robert E. Anderson Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Claude Nicaise Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Michael J. O'Donnell Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Richard Jon Barry Director 15,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Patrick J. Scannon Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Sanford R. Robertson Director 308,740 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 1, 2024 Sanford R. Robertson Director 354,740 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Sanford R. Robertson Director 72,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 26, 2024 Richard Jon Barry Director 176,085 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 26, 2024 Richard Jon Barry Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2024 Eric J. Schoen Chief Financial Officer 6,920 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2024 Eric J. Schoen Chief Financial Officer 800 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cassava Sciences in the News